Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rang in aandelen #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Aandeelprijs
$23.57
Laatst gesynchroniseerd: 2026-08-20
Marktkapitalisatie
$51.76M
Verandering (1 dag)
-0.08%
Verandering (1 jaar)
289.59%
Land
US
Handel Apollomics, Inc. (APLM)

Categorie

P/S-ratio voor Apollomics, Inc. (APLM)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Apollomics, Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Apollomics, Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US